Last reviewed · How we verify
Allergan — Portfolio Competitive Intelligence Brief
58 marketed
0 filed
35 Phase 3
54 Phase 2
24 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Botox | ONABOTULINUMTOXINA | marketed | Acetylcholine Release Inhibitor [EPC] | SNAP-25 | Neuroscience | 2010-01-01 |
| GoodSense Eye Drops Advanced Relief Moisturizer | DEXTRAN | marketed | Plasma Volume Expander [EPC] | Ophthalmology | 1978-01-01 | |
| bimatoprost ophthalmic solution 0.03% | bimatoprost ophthalmic solution 0.03% | marketed | ||||
| Dexamethasone intravitreal implant | Dexamethasone intravitreal implant | marketed | ||||
| latanoprost 0.005% | latanoprost 0.005% | marketed | ||||
| Botulinum Toxin Type A 150kDa | Botulinum Toxin Type A 150kDa | marketed | ||||
| AGN-190584 | AGN-190584 | marketed | Other | |||
| Bystolic | nebivolol | marketed | 5-hydroxytryptamine receptor 1A, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor | Cardiovascular | ||
| travoprost 0.004% | travoprost 0.004% | marketed | ||||
| IV Placebo (Saline) | IV Placebo (Saline) | marketed | ||||
| Lubricant Eye Drops (Optive™) | Lubricant Eye Drops (Optive™) | marketed | Artificial tear / Lubricant | Ophthalmology | ||
| Oxymetazoline HCL Cream 1.0% | Oxymetazoline HCL Cream 1.0% | marketed | Alpha-1 adrenergic agonist | Alpha-1 adrenergic receptor | Dermatology |
Therapeutic area mix
- Ophthalmology · 47
- Dermatology · 10
- Neurology · 7
- Ophthalmology / Infectious Disease · 4
- Cardiovascular · 3
- Endocrinology / Musculoskeletal · 2
- Diabetes · 2
- Neurology; Aesthetics; Ophthalmology · 2
- Immunology · 1
- Musculoskeletal / Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Pfizer · 8 shared drug classes
- Merck Sharp & Dohme LLC · 7 shared drug classes
- GlaxoSmithKline · 7 shared drug classes
- Bausch & Lomb Incorporated · 5 shared drug classes
- AbbVie · 5 shared drug classes
- Novartis · 5 shared drug classes
- AstraZeneca · 4 shared drug classes
- Assistance Publique - Hôpitaux de Paris · 4 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Allergan:
Cite this brief
Drug Landscape (2026). Allergan — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allergan. Accessed 2026-05-13.